title: Effects of medical therapy or surgery on prostatic and bladder resistive indices in patients with benign prostatic hyperplasia.
abstract: BACKGROUND
  The effects of medical therapy or surgery on bladder and prostatic resistive indices (RIs) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) were evaluated in the present study.
  
  
  METHODS
  A total of 124 consecutive LUTS/BPH patients who were candidates for medical therapy (alfuzosin 10 mg once daily, n=66) or surgery (transurethral prostatectomy (TUR-P), n=58) were prospectively included. Baseline assessment of patients was performed with the International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), and prostatic and bladder RIs measured using power Doppler imaging (PDI). All patients were re-evaluated 3 months after treatment measuring the same parameters.
  
  
  RESULTS
  Following medical therapy, mean IPSS (17.2±5.1 vs. 8.3±5.3, p=0.0001), postvoiding residual (PVR) urine (80.0±80.5 vs. 40.3±38.6, p=0.0001), and prostatic RI (0.73±0.1 vs. 0.70±0.1, p=0.0001) were decreased, Qmax (13.7±4.2 vs. 16.9±5.9, p=0.0001) was increased, and bladder RI remained unchanged (0.70±0.1 vs. 0.70±0.1, p=0.68). Mean IPSS (25.3±5.6 vs. 6.0±4.5, p=0.0001), PVR urine volume (134.5±115.5 vs. 35.7±25.9, p=0.0001), and prostatic (0.78±0.1 vs. 0.67±0.04, p=0.0001) and bladder RIs (0.72±0.1 vs. 0.64±0.04, p=0.005) were decreased, and Qmax (8.0±4.5 vs. 17.2±8.2, p=0.0001) was increased after TUR-P.
  
  
  CONCLUSIONS
  Our results demonstrated that TUR-P decreased both prostatic and bladder RIs, while α-blocker therapy did not change bladder RI in the early posttreatment period in LUTS/BPH patients.
authors.affiliation: Urology Clinic, Numune Training and Research Hospital, Ankara, Turkey.
authors.forename: Suleyman
authors.initials: S
authors.lastname: Bulut
authors.forename: Cuneyt
authors.initials: C
authors.lastname: Ozden
authors.forename: Binhan Kagan
authors.initials: BK
authors.lastname: Aktas
authors.forename: Tagmac
authors.initials: T
authors.lastname: Deren
authors.forename: Suleyman
authors.initials: S
authors.lastname: Tagci
authors.forename: Cevdet Serkan
authors.initials: CS
authors.lastname: Gokkaya
authors.forename: Mehmet Murat
authors.initials: MM
authors.lastname: Baykam
authors.forename: Ali
authors.initials: A
authors.lastname: Memis
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use*; D000368:Aged; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D011799:Quinazolines / Q000627:therapeutic use*; D020127:Recovery of Function; D013997:Time Factors; D016896:Treatment Outcome; D018608:Ultrasonography, Doppler; D001743:Urinary Bladder / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology; D014563:Urodynamics / Q000187:drug effects; D064804:Urological Agents / Q000627:therapeutic use*
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D011799:Quinazolines; D064804:Urological Agents; C047638:alfuzosin